Boston Scientific (BSX) 8-K Current Report: February 23, 2026
Filed: February 23, 2026
Health Care
Surgical & Medical Instruments & ApparatusBoston Scientific (BSX) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items3 items
- Item 5.02: Departure/Election of Directors or Officers
- Item 7.01: Regulation FD Disclosure
- Item 8.01: Other Events
Boston Scientific 8-K Feb 23, 2026 Event Analysis
Item 5.02 · Departure/Election of Directors or Officers
- • Board expanded from 10 to 12 directors; Catherine R. Smith and Christophe P. Weber appointed effective Feb 18, 2026
- • Each new director receives prorated cash retainer ~$24,663 (vs. $125,000 annual) and equity award ~$42,420 (vs. $215,000 annual)
- • Equity grants priced March 2, 2026; vest at end of director term at 2026 Annual Meeting
- • Smith joins Audit and Nominating/Governance Committees; Weber joins Executive Compensation and Risk, Science & Technology Committees
- • Standard indemnification agreements to be executed; no related-party conflicts disclosed for either appointee
Item 7.01 · Regulation FD Disclosure
- • Reg FD filing contains only standard non-incorporation disclaimer — no material business update, guidance, or data disclosed in this excerpt
Item 8.01 · Other Events
- • Board approved $4.0B increase to share repurchase authorization on Feb 18, 2026, bringing total program to $5.0B
- • Full $5.0B remains available — no buybacks executed against new authorization yet
- • Large buyback signal: $5.0B represents significant capital return commitment, bullish on BSX valuation at current levels
Other Boston Scientific 8-K Filings
Get deeper insights on Boston Scientific
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.